[BMY] Bristol-Myers Squibb Company


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 128.21 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 59.6 Change: 0.82 (1.4%)

chart BMY

Refresh chart

Strongest Trends Summary For BMY

BMY is in the medium-term down -14% in 7 months. In the long-term down -23% below S&P in 1 year and up 175% in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding1.67 B EPS2.51 EPS Growth - 4 Quarters-704.03% EPS Growth - Q/Q-233.04%
EPS Growth - Y/Y-255.12% Sales Growth - 4 Quarters 6.17% Sales Growth - Q/Q3.02% P/E21.7
P/E To EPS Growth0.28 P/S7.83 P/BV8.48 Price/Cash Per Share23.41
Price/Free Cash Flow48.9 ROA5.6% ROE11.84% ROI7.56%
Current Ratio1.76 Quick Ratio1.58 Long Term Debt/Equity1.18 Debt Ratio0.49
Gross Margin76.6% Operating Margin14.94% Net Profit Margin10.93% Dividend Payout Ratio-136.15%
Dividend Yield-1.9%
Fundamental Data
Cash From Financing Activities-1.57 B Cash From Investing Activities-526 M Cash From Operating Activities697 M Gross Profit3.18 B
Net Profit-130 M Operating Profit45 M Total Assets31.95 B Total Current Assets13.06 B
Total Current Liabilities7.44 B Total Debt7.37 B Total Liabilities16.83 B Total Revenue4.16 B
Technical Data
High 52 week68.98 Low 52 week45.12 Last close50.65 Last change-0.65%
RSI48.82 Average true range1.1 Beta0.67 Volume5.04 M
Simple moving average 20 days0.81% Simple moving average 50 days1.69% Simple moving average 200 days-10.51%
Performance Data
Performance Week-1.97% Performance Month3.33% Performance Quart-4.5% Performance Half-15.08%
Performance Year-16.42% Performance Year-to-date-1.67% Volatility daily1.33% Volatility weekly2.98%
Volatility monthly6.12% Volatility yearly21.18% Relative Volume180.93% Average Volume14.91 M
New High New Low


2019-03-24 13:00:52 | Is It Safe to Buy Biogen Stock Right Now?

2019-03-22 09:15:01 | Why Bristol-Myers Squibb BMY is a Great Dividend Stock Right Now

2019-03-21 10:10:02 | Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

2019-03-21 10:03:02 | Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

2019-03-21 07:30:00 | Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.

2019-03-20 17:45:09 | Bristol-Myers Squibb BMY Dips More Than Broader Markets: What You Should Know

2019-03-20 11:30:03 | Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

2019-03-19 21:33:00 | Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?

2019-03-19 15:17:06 | Analysts Have Revised BMY’s Target Price Downward in March

2019-03-19 14:17:00 | Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.

2019-03-19 13:14:00 | Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

2019-03-19 11:56:03 | Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

2019-03-19 09:53:00 | Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

2019-03-19 09:45:11 | Bristol-Myers Squibb and Starboard Value square off over Celgene deal

2019-03-19 08:40:12 | Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

2019-03-19 07:00:00 | Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene

2019-03-19 06:59:00 | Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

2019-03-18 22:34:28 | U.S. FDA approves Roche's small cell lung cancer treatment

2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

2019-03-18 15:53:07 | Novartis' NVS Alcon Acquired PowerVision for $285 Million

2019-03-17 11:45:00 | AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

2019-03-15 14:00:00 | Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?

2019-03-15 11:37:03 | Infinity Inks Deal With Roche for Phase II Study of IPI-549

2019-03-15 11:28:03 | Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

2019-03-15 10:31:02 | Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

2019-03-15 09:46:07 | Some Bristol-Myers Squibb NYSE:BMY Shareholders Are Down 25%

2019-03-15 05:05:09 | J&J Seeks Approval for Darzalex in Expanded Patient Group

2019-03-14 09:32:49 | U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

2019-03-14 09:09:23 | U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

2019-03-13 17:31:31 | 5 Biotech Stocks to Keep an Eye on in 2019

2019-03-13 16:37:00 | Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says

2019-03-13 12:27:00 | A Merck Cancer Treatment Has a Big Opportunity in China, Analyst Says

2019-03-12 10:24:41 | See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

2019-03-12 10:07:02 | Celgene CELG Submits Application for MS Drug in Europe

2019-03-12 10:01:02 | Pfizer's PFE Kidney Cancer Drug Combo Gets EMA's Validation

2019-03-12 06:06:00 | 3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade

2019-03-12 02:04:01 | Biocartis Group NV: Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies

2019-03-11 18:14:18 | Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source

2019-03-11 13:41:00 | Here's Why Seres Therapeutics Stock Soared Today

2019-03-11 12:26:04 | Bayer Submits Application in EU for Prostate Cancer Drug

2019-03-11 11:06:03 | Is Bristol-Myers BMY a Solid Pick for Value Investors?

2019-03-08 11:04:04 | Celldex CLDX Q4 Loss Narrower than Expected, Sales Beat

2019-03-08 07:30:58 | How Novartis Is Transforming Its Structure in 2019

2019-03-08 00:49:59 | [$$] Why old-school asset managers are copying the activists

2019-03-07 17:22:00 | Bristol-Myers Squibb Announces Dividend

2019-03-07 11:58:00 | I Like the Long Side of Bristol-Myers Squibb

2019-03-07 10:31:14 | BMY and NVS: How Tax Rates and Interest Expenses Stack Up

2019-03-07 09:01:13 | How Novartis and BMY’s Dividend Profiles Stack Up

2019-03-07 07:32:14 | Novartis or BMY: Who’s Controlling Expenses Better?

2019-03-06 20:52:02 | Cramer Remix: This is something Bristol-Myers should do